IP Library Granted Patent US 8,846,954
Granted Patent B2
US 8,846,954 · App. 11/817,166 · Granted Sep 30, 2014

Crystallisation and purification of glycopyrronium bromide

Inventors: Andrew Douglas Baxter (Cambridge, GB); Kenneth Walter Sinden (Essex, GB); Stefan Kleinebekel (Bielefeld, DE)
Assignee: Sosei R&D Ltd.
C07D207/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,846,954
App. No.
11/817,166
Granted
Sep 30, 2014
Kind
B2
Abstract

A method for the production of crystalline glycopyrronium bromide, comprises the reaction of glycopyrronium base with methyl bromide in a solvent, in which the solvent is selected such that the diastereoisomeric ratio of the product favors the R,S and S,R diastereoisomers over the R,R, and S,S diastereoisomers, and separating the desired diastereoisomers by one or more controlled crystallization steps. This method gives a product having a particle size of narrow distribution.

Claims (9)

1. A method for the production of crystalline glycopyrronium bromide in the form of predominantly the R,S and S,R diastereoisomers with respect to the R,R, and S,S diastereoisomers, which comprises reacting glycopyrronium base, in acetate acetone, with methyl bromide and then separating the desired diastereoisomers by a controlled crystallization step conducted in a solvent comprising the same or different compounds of the formula R 1 COR 2 or R 1 COOR 2 wherein R 1 and R 2 are independently C 1-8 alkyl, wherein the diasteroisomeric ratio of the glycopyrronium bromide is at least 60:40 in favour of the R,S/S,R-pair.

2. The method according to claim 1 , wherein the crystallisation solvent comprises a ketone of the formula R 1 COR 2 .

3. The method according to claim 2 , wherein the crystallisation solvent comprises a higher ketone than acetone.

4. The method according to claim 3 , wherein the crystallisation solvent comprises methyl ethyl ketone or methyl isobutyl ketone.

5. The method according to claim 4 , wherein the crystallisation solvent is a mixture of methyl ethyl ketone and methanol.

6. The method according to claim 1 , wherein the particle size of the product is less than 100 μm.

7. The method according to claim 6 , wherein the particle size is less than 50 μm.

8. The method according to claim 1 , further comprising one or more additional controlled crystallization steps conducted in a solvent comprising the same or different compounds of the formula R 1 COR 2 or R 1 COOR 2 wherein R 1 and R 2 are independently C 1-8 alkyl.

9. The method according to claim 8 , wherein the diastereoisomeric purity of the product is more than 99.8% R,S/S,R.

Assignments (4)
CHANGE OF NAME Recorded Jul 16, 2024
From: HEPTARES THERAPEUTICS LIMITED
To: NXERA PHARMA UK LIMITED
Reel/Frame 067998/0421 →
CHANGE OF ADDRESS FOR ASSIGNEE Recorded Jul 16, 2024
From: HEPTARES THERAPEUTICS LIMITED
To: HEPTARES THERAPEUTICS LIMITED
Reel/Frame 068384/0451 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2018
From: SOSEI R&D LTD.
To: HEPTARES THERAPEUTICS LIMITED
Reel/Frame 047831/0220 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2008
From: BAXTER, ANDREW DOUGLAS; SINDEN, KENNETH WALTER; KLEINEBEKEL, STEFAN
To: SOSEI R&D LTD.
Reel/Frame 020854/0854 →
Priority Claims (1)
GB 0504463.1 · Mar 3, 2005 · national
Continuity (1)
Related Publication 20080227988A1 · Sep 18, 2008